On the bangs of its quarterly trading update, bioMérieux announced its new five-year strategic plan "GO28", which notably targets organic sales growth of 7% on average per annum over 2024-28.

The group also aims to increase its operating profit from ordinary activities to 20% of sales in 2028, at constant exchange rates and scope of consolidation (compared with 16.5% in 2023), with annual organic growth of at least 10% per annum until 2028.

Finally, the in vitro diagnostics specialist forecasts annual capital expenditure of between 8% and 10% of sales over the 2025-28 period, as well as a dividend payout ratio of around 25% of net income, group share.

Copyright (c) 2024 CercleFinance.com. All rights reserved.